**Breaking News** LIttle Known Biotech Company Does $41 Million In Q1!

Revenues continue to explode for this growing MedTech firm that just got another price increase from Zack's Small Cap Research to $23.25![ ͏  ͏ ­ ­ Unsubscribe A Message from Huge Alerts Revenues continue to explode for this growing MedTech firm that just got another price increase from Zack’s Small Cap Research to $23.25! The growing MedTech arena is home to some notable players but one company is uniquely standing out as its revenues explode, purchase orders accelerate, and a price target from Zack’s Small Cap Research continues to move north. This Company is changing the skin graft market by using the natural properties of perinatal tissue. Growth is rocketing as management makes smart and aggressive moves. Following 2023, a year of tremendous growth, this stock recently released its Q1 financial results of $ 41 million that revealed the company’s first positive net income! The company attributes its growth to the successful launch of the company’s Amniowrap2™, an innovative placental-derived allograft product designed to address a broad spectrum of wound applications. A significant factor contributing to this success has been the widespread acceptance and utilization of Amniowrap2™ by medical professionals, underscoring its effectiveness and growing prominence in the healthcare industry. The Stock especially gained momentum in the second half of 2023 when the Centers awarded the company a valuable Q code for its Vendaje AC and AmnioWrap2 products for Medicare and Medicaid Services. Most recently, the company announced that its Healthcare Common Procedure Coding System code for Vendaje AC became effective and that the Center for Medicare Services established national pricing for AmnioWrap2 in all 50 states and territories. Additionally, the company isn’t resting on its success as management recently initiated a clinical trial evaluating Vendaje in diabetic foot ulcers—a market with enormous and growing potential! The Stock additionally sees an uplisting to a major exchange sooner than later! Learn more about why Zack’s has increased its price target on this stock to a whopping $23.25!

This message is a paid advertisement sent on behalf of Huge Alerts, a third-party advertiser of MarketBeat. Why did I receive this email?     This message is a paid advertisement for BioStem Technologies Inc. (OTC: BSEM) from Sideways Frequency and Huge Alerts. American Consumer News, LLC dba MarketBeat receives a fixed fee for each subscriber that clicks on a link in this email, totaling up to $5,000. Other than the compensation received for this advertisement sent to subscribers, MarketBeat and its principals are not affiliated with either Sideways Frequency or Huge Alerts. MarketBeat and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither MarketBeat nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from MarketBeat to buy or sell any security. MarketBeat has not evaluated the accuracy of any claims made in this advertisement. MarketBeat recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioStem Technologies Inc. (OTC: BSEM) on Huge Alerts' website for additional information about the relationship between Huge Alerts and BioStem Technologies Inc. (OTC: BSEM).     If you have questions about your subscription, feel free to contact our U.S. based support team via email at contact@marketbeat.com.   If you would no longer like to receive promotional emails from MarketBeat advertisers, you can unsubscribe or manage your mailing preferences here.   © 2006-2024 MarketBeat Media, LLC. 345 N Reid Place, Suite 620, Sioux Falls, SD 57103. United States.   Today's Bonus Content: Discover 2024's AI Investment Front-Runners! 🌟 (Click to Opt-in)